BioXcel Therapeutics Inc
BTAI1.730USD
-0.100-5.46%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
34.59MMarket Cap
LossP/E TTM
More Details of BioXcel Therapeutics Inc Company
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
BioXcel Therapeutics Inc Info
Ticker SymbolBTAI
Company nameBioXcel Therapeutics Inc
IPO dateMar 08, 2018
CEOMehta (Vimal)
Number of employees37
Security typeOrdinary Share
Fiscal year-endMar 08
Address555 Long Wharf Dr
CityNEW HAVEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06511-6107
Phone12036438060
Websitehttps://www.bioxceltherapeutics.com/
Ticker SymbolBTAI
IPO dateMar 08, 2018
CEOMehta (Vimal)
Company Executives of BioXcel Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
382.05K
+1792.63%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
-7.69%
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
11.69K
+56.10%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
7.28K
+8.15%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
7.06K
+8.42%
Mr. Erik Kopp
Mr. Erik Kopp
Investor Relations
Investor Relations
--
--
DR. Frank D. Yocca ,Ph.D.
DR. Frank D. Yocca ,Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Dr. Rajiv Patni, M.D.
Dr. Rajiv Patni, M.D.
Independent Director
Independent Director
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
382.05K
+1792.63%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
-7.69%
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
11.69K
+56.10%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
7.28K
+8.15%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
7.06K
+8.42%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Millennium Management LLC
4.70%
Bioxcel Corp
2.20%
Mehta (Vimal)
1.75%
Armistice Capital LLC
1.32%
Oaktree Capital Management, L.P.
1.30%
Other
88.74%
Shareholders
Shareholders
Proportion
Millennium Management LLC
4.70%
Bioxcel Corp
2.20%
Mehta (Vimal)
1.75%
Armistice Capital LLC
1.32%
Oaktree Capital Management, L.P.
1.30%
Other
88.74%
Shareholder Types
Shareholders
Proportion
Hedge Fund
6.04%
Investment Advisor
2.97%
Investment Advisor/Hedge Fund
2.28%
Corporation
2.20%
Individual Investor
2.06%
Venture Capital
0.52%
Research Firm
0.28%
Family Office
0.02%
Other
83.65%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
154
2.64M
5.25%
--
2025Q3
183
2.64M
5.94%
+1.74M
2025Q2
207
906.57K
17.47%
+238.13K
2025Q1
223
670.27K
15.23%
-162.30K
2024Q4
234
472.39K
22.38%
+270.52K
2024Q3
245
201.96K
36.09%
-344.33K
2024Q2
257
627.65K
50.00%
-176.74K
2024Q1
257
597.13K
45.43%
-357.78K
2023Q4
258
602.91K
51.50%
-65.53K
2023Q3
266
667.23K
71.43%
-474.33K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Millennium Management LLC
1.03M
5.23%
+1.03M
--
Sep 29, 2025
Bioxcel Corp
480.34K
2.44%
-53.83K
-10.08%
Jun 06, 2024
Mehta (Vimal)
20.19K
0.1%
+382.00
+1.93%
Sep 15, 2025
Armistice Capital LLC
288.13K
1.47%
-24.20K
-7.75%
Mar 31, 2025
Oaktree Capital Management, L.P.
284.10K
1.45%
+284.10K
--
Jun 30, 2025
The Vanguard Group, Inc.
18.82K
0.1%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
28.18K
0.14%
+6.12K
+27.74%
Jun 30, 2025
XTX Markets LLC
23.42K
0.12%
+23.42K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
17.78K
0.09%
-5.09K
-22.26%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Russell 3000 ETF
0%
iShares Neuroscience and Healthcare ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
View more
iShares Russell 3000 ETF
Proportion0%
iShares Neuroscience and Healthcare ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Date
Type
Ratio
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
FAQs
Who are the top five shareholders of BioXcel Therapeutics Inc?
The top five shareholders of BioXcel Therapeutics Inc are:
Millennium Management LLC holds 1.03M shares, accounting for 5.23% of the total shares.
Bioxcel Corp holds 480.34K shares, accounting for 2.44% of the total shares.
Mehta (Vimal) holds 20.19K shares, accounting for 0.10% of the total shares.
Armistice Capital LLC holds 288.13K shares, accounting for 1.47% of the total shares.
Oaktree Capital Management, L.P. holds 284.10K shares, accounting for 1.45% of the total shares.
Millennium Management LLC holds 1.03M shares, accounting for 5.23% of the total shares.
Bioxcel Corp holds 480.34K shares, accounting for 2.44% of the total shares.
Mehta (Vimal) holds 20.19K shares, accounting for 0.10% of the total shares.
Armistice Capital LLC holds 288.13K shares, accounting for 1.47% of the total shares.
Oaktree Capital Management, L.P. holds 284.10K shares, accounting for 1.45% of the total shares.
What are the top three shareholder types of BioXcel Therapeutics Inc?
The top three shareholder types of BioXcel Therapeutics Inc are:
Millennium Management LLC
Bioxcel Corp
Mehta (Vimal)
Millennium Management LLC
Bioxcel Corp
Mehta (Vimal)
How many institutions hold shares of BioXcel Therapeutics Inc (BTAI)?
As of 2025Q4, 154 institutions hold shares of BioXcel Therapeutics Inc, with a combined market value of approximately 2.64M, accounting for 5.25% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.69%.
What is the biggest source of revenue for BioXcel Therapeutics Inc?
In --, the -- business generated the highest revenue for BioXcel Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
